Framatome and Global Morpho Pharma announced a service agreement for the development of a high-capacity technology for the purification of medical radioisotope non-carrier-added (n.c.a.) Lutetium-177 (Lu-177). This will contribute to aligning production capacity with the increasing demand for this radioisotope and will serve innovations and developments in cancer treatments.
The global demand for n.c.a.
Lu-177 is expected to increase 15-fold by 2030 to reach a number of 300,000
patients, that are predicted to be treated. Initiatives across the
manufacturing chain are needed to align the production with this growing
demand. Global Morpho Pharma’s technology will enable a significant increase in
target processing capacity and contribute to securing the supply of n.c.a Lu-177.
To read more please visit:
Source: Framatome